Discolored, Tender Spots on the Face

January 10th 2025

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

January 8th 2025

FDA Greenlights New Treatment for Moderate-to-Severe Atopic Dermatitis: Daily Dose

Your daily dose of the clinical news you may have missed.

January 6th 2025

FDA Receives sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years

Your daily dose of the clinical news you may have missed.

FDA Accepts sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years / image credit DOCS Dermatology Rocco Serrao, MD

FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis

Arcutis Biotherapeutics announced submission of the sNDA today, citing the the supporting positive data from the phase 3 INTEGUMENT-PED and INTEGUMENT-OLE trials.

Tapinarof Cream, 1%, Gets FDA Green Light for Atopic Dermatitis in Individuals Aged 2 Years and Older

Nemolizumab is the first approved monoclonal antibody that targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis

Approval for the topical nonsteroidal therapy, based on data from the phase 3 ADORING clinical trial program, helps fill a gap in current offerings for atopic dermatitis.

Related Content

January 10th 2025

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

January 8th 2025

FDA Greenlights New Treatment for Moderate-to-Severe Atopic Dermatitis: Daily Dose

Your daily dose of the clinical news you may have missed.

January 6th 2025

FDA Receives sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years

Your daily dose of the clinical news you may have missed.

FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis

Arcutis Biotherapeutics announced submission of the sNDA today, citing the the supporting positive data from the phase 3 INTEGUMENT-PED and INTEGUMENT-OLE trials.

Tapinarof Cream, 1%, Gets FDA Green Light for Atopic Dermatitis in Individuals Aged 2 Years and Older

Nemolizumab is the first approved monoclonal antibody that targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.